Breaking news headlines, stories and live updates on current affairs from across the globe. Complete coverage on the latest ...

We rarely invite the same band back to the Tiny Desk. But the beloved Kronos Quartet, which first played our offices 12 years ago, isn't the same band. Three of the four members are brand new: Cellist ...

It’s the end of an era. Cronus has moved rapidly after RICOCHET has announced they are targeting Cronus Zen and XIM Matrix for Call Of Duty. RICOCHET revealed in the latest Call of Duty Updates post ...

SPOILER ALERT! This post contains major plot details from the first four episodes of Netflix‘s Stranger Things 5. The Hawkins crew are set for one last adventure in Stranger Things 5, which debuted ...

Kratos’ journey through Norse mythology is fully explained. His battles with gods and monsters redefine his role as a father and warrior. Trump pardons 5 former NFL stars for wide-ranging crimes FBI ...

The massively successful launch of Battlefield 6 spawns a controversy over Cronus Zen, previously touted as an undetectable form of cheating. Battlefield 6 is reportedly banning players detected using ...

The Battlefield 6 community is torn on EA’s decision to ban players who are using Cronus Zen devices. Cronus Zen is a plug-in input adapter that allows FPS players to basically cheat. Using scripts ...

Jake Valentine is a Staff Writer at DualShockers with more than two decades of experience covering the video game industry. Since 2004, he has written about games across news, reviews, guides, lists, ...

Dominik Bošnjak is a freelance writer from Croatia. He has been writing about games for as long as he can remember and began doing so professionally in 2010 because an opportunity presented itself ...

Ignota Labs has harvested more assets for its drug candidate rehabilitation scheme, snapping up Kronos Bio’s clinical pipeline months after a series of setbacks drove the biotech off public markets. U ...

CAMBRIDGE, England--(BUSINESS WIRE)--Ignota Labs, the AI drug turnaround company, has announced its acquisition of Kronos’s clinical assets, istisociclib, a CDK9 inhibitor, and entospletinib and ...